Analysis Tools
growth/size/body
|
• modest alveolar bone loss at 30 weeks
|
|
• at 28 weeks, mutant animals weigh less
|
adipose tissue
homeostasis/metabolism
|
• decreased plasma leptin concentrations at 28 weeks of age
|
|
• decreased fasting plasma glucose concentrations at 28 weeks of age
|
|
• decreased plasma insulin concentrations at 28 weeks of age
|
|
• decreased plasma triglyceride concentrations at 28 weeks of age
|
|
• DMBA and TPA-treated mice exhibit papillomas that develop with a greater latency than in similarly treated wild-type mice
DMBA and TPA-treated mice exhibit papillomas that develop with a greater latency than in similarly treated wild-type mice
however, malignant progression of tumors is normal
• however, malignant progression of tumors is normal
|
immune system
| N |
• mutant spleen cells isolated 49 days after myelin oligodendrocyte glycoprotein (MOG) display lack of autoimmune T cell responses (proliferation) to MOG peptide, similar to wild-type spleen cells
|
|
• organized follicular dendritic cell networks are absent
|
|
• absence of splenic primary B cell follicles
|
|
• inability to form organized germinal centers
(J:47673)
• after immunization with sheep red blood cells (SRBCs), mutants fail to form organized germinal centers
(J:114740)
|
|
• after intraperitoneal injection of SRBC, mutants exhibit severely impaired SRBC-specific IgG1 antibody responses
|
|
• LPS-stimulated thioglycollate-elicited peritoneal macrophages (TEPMs) cannot induce thymocyte proliferation, but stimulated TEPMs in wild-type and Tnftm3Gki homozygotes induce thymocyte proliferation with equal efficiency
|
|
• organized follicular dendritic cell networks are absent
|
|
• the typical subepithelial dome areas fail to form
|
|
• B cells are present but no organized follicles are seen and organized follicular dendritic cell networks are absent
|
|
• average of 2 - 4 per mouse compared to 6 - 8 in wild-type mice
|
|
• mesenteric lymph nodes (MLN) lack organized B cell follicles but occasionally have GC-like regions that are centered in B cell areas
|
|
• B cell follicles and follicular dendritic cell network formation are impaired in mesenteric and peripheral lymph nodes; however, B cells are present and B and T cell areas are segregated
|
|
• 16 days post-immunization with pertussis toxin, mutants begin to show clinical signs of experimental allergic encephalomyelitis (EAE) which progresses to chronic non-remitting disease compared to wild-type mice which show signs of EAE at 12 days post-injectiona and peak EAE occurs at ~15 days, with gradual remission and results in only a mild deficit
|
|
• when treated with D-gal (a hepatotoxin) at 20 mg/animal and doses of lipopolysaccharide (LPS) up to 100ug/25g body weight, mutants are completely resistant to LPS-induced death, but wild-type mice all die at 100-fold lower LPS doses
|
|
• in the skin following treatment with TPA compared with similarly treated wild-type mice
|
|
• impaired contact hypersensitivity response
|
|
• susceptibility to death from Listeria monocytogenes infection
(J:47673)
• with challenge at high doses (10000 cfu) of Listeria monocytogenes (LM), mutants show high sensitivity with maximal lethality at 6 days post-infection, compared to wild-type; mutants are highly sensitive when challenged with a physiological dose of LM (100 cfu) compared to wild-type
(J:114740)
|
hematopoietic system
|
• organized follicular dendritic cell networks are absent
|
|
• absence of splenic primary B cell follicles
|
|
• inability to form organized germinal centers
(J:47673)
• after immunization with sheep red blood cells (SRBCs), mutants fail to form organized germinal centers
(J:114740)
|
|
• after intraperitoneal injection of SRBC, mutants exhibit severely impaired SRBC-specific IgG1 antibody responses
|
|
• LPS-stimulated thioglycollate-elicited peritoneal macrophages (TEPMs) cannot induce thymocyte proliferation, but stimulated TEPMs in wild-type and Tnftm3Gki homozygotes induce thymocyte proliferation with equal efficiency
|
neoplasm
|
• DMBA and TPA-treated mice exhibit papillomas that develop with a greater latency than in similarly treated wild-type mice
DMBA and TPA-treated mice exhibit papillomas that develop with a greater latency than in similarly treated wild-type mice
however, malignant progression of tumors is normal
• however, malignant progression of tumors is normal
|
craniofacial
|
• modest alveolar bone loss at 30 weeks
|
skeleton
|
• modest alveolar bone loss at 30 weeks
|
|
• significantly increased
|
|
• 32% increase in trabecular bone volume
|
integument
|
• following DMBA and TPA treatment compared with similarly treated wild-type mice
|
cellular
|
• following DMBA and TPA treatment compared with similarly treated wild-type mice
|
